Twist Bioscience Corp

  • Health Technology
  • Biotechnology


$37 ▼-0.216%

Extented Hours




35.14 - 37.25


25.07 - 139.99

Join Discuss about TWST with like-minded investors

@viking #StockTraders.NET

Upside: -ENOB +159% (announces FDA Acceptance of Pre-IND Request for Potential HIV Cure) -ITOS +51% (GSK and iTeos announce development and commercialisation collaboration for EOS-448) -CRSR +15% (hearing interest from WallStreetBets) -NVAX +9.0% (COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in PREVENT-19 Phase 3 trial) -LPCN +8.3% (FDA clears LPCN 1154 IND application for a Phase 2 Postpartum Depression Study) -RIOT +8.3% (crypto strength following TSLA CEO Musk indicating car maker may resume BTC transactions) -HAPP +7.8% (signed agreement to distribute Volkswagen Electric Vehicles) -MARA +7.8% (crypto strength following TSLA CEO Musk indicating car maker may resume BTC transactions) -RAPT +7.7% (reports positive topline results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis) -AMTX +6.0% (signs $200M biofuels offtake agreement with international renewable fuels supplier Murex, LLC to be delivered during 2021 to 2023) -OCC +5.4% (earnings) -EFOI +4.8% (enters marketing partnership with FirstEnergy Home and FirstEnergy Advisors) -TWST +3.2% (collaborates with Regeneron for production of genotyping by sequencing panel to enable diverse genome-wide screening) -HGEN +2.8% (initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA)) -CODA +2.3% (earnings) -OTLK +2.3% (announces inclusion in the Russell 2000 Index, effective June 25, 2021) -SVOK +1.1% (confirms Boxed to go public through merger with Seven Oaks Acquisition Corp. in deal valued at ~$900M) Downside: -ATXI -47% (receives Complete Response Letter from the FDA for IV Tramadol, saying it does not support benefits as a monotherapy) -RIDE -11% (CEO and CFO resign following results of special committee investigation of Hindenburg Research report) -HEXO -3.6% (earnings) -NKLA -1.5% (discloses entered into a purchase agreement and a registration rights agreement with Tumim Stone Capital to sell $300M of the Nikola's common stock)

56 Replies 11 👍 8 🔥

Key Metrics

Market Cap

2.09 B



Avg. Volume

1.35 M

Shares Outstanding

56.26 M



Public Float


Next Earnings Date


Next Dividend Date

Company Information

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by 'writing' DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

CEO: Emily Leproust


HQ: 681 Gateway Blvd. South San Francisco, 94080 California

Related News